Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma

Sponsor
Gruppo Oncologico Italiano di Ricerca Clinica
Study ID
NCT07460245
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Avelumab 800 mg flat-dose IV — DRUG
    Avelumab 800 mg flat-dose IV every 2 weeks

Study Details

This study represents an innovative opportunity in the treatment of metastatic urothelial carcinoma

Key Dates

First listed
Mar 10, 2026
Start date
Jun 30, 2026
Status verified
Feb 2026
Primary completion
Jun 30, 2026
Completion
Dec 31, 2030

Study Design

Enrollment
144 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A
    Avelumab 800 mg flat-dose IV every 2 weeks plus BSC
  • No Intervention: Arm B
    BSC alone

Primary Outcome Measure

Primary Endopoint [ Time Frame: At 12 months from randomization ]

Central Contacts

Find similar trials

Nationwide
Bladder cancer trialsOncology trialsUrology trials

Related Studies